Progestin only pills usage method composition n brand names
Reading File
Finding Sources
Searching the Web
progestin only pills composition brand names usage method 2024
Finding Sources
Reading Web Page
progestin only pills composition brand names usage method
Reading File
Reading File
Reading File
Finding Sources
Finding Sources
Reading File
Now I have enough information for a comprehensive answer. Here it is:
Progestin-Only Pills (POPs) - "Mini-Pills"
What Are They?
Progestin-only pills (POPs), also called "mini-pills," contain only a progestogen with no estrogen component. They are taken continuously every day with no hormone-free interval.
Composition
There are three main formulations currently available:
1. Norethindrone (Norethisterone)
- Dose: 0.35 mg per tablet (traditional POP)
- A 19-norprogestin with moderate potency
- The most widely used traditional POP worldwide
2. Norgestrel
- Dose: 0.075 mg per tablet
- Also a 19-norprogestin; levonorgestrel is its active isomer
- Available in the US as a POP formulation
3. Drospirenone (DRSP)
- Dose: 4 mg per tablet (higher hormone dose)
- A newer, spironolactone-derived progestin with anti-mineralocorticoid effects (similar to spironolactone - theoretical risk of hyperkalemia)
- Comes in a 24 active + 4 placebo pill pack (unlike traditional 28 active pills)
- Primary mechanism is ovulation inhibition (similar to combined OCs), making it more effective than older POPs
- Lippincott Pharmacology, p. 849
Mechanism of Action
POPs work through multiple mechanisms:
- Cervical mucus thickening - makes it impenetrable to sperm (primary mechanism for norethindrone/norgestrel)
- Endometrial thinning - making it unsuitable for implantation
- Inhibition of ovulation - inconsistent with traditional norethindrone POPs; the primary mechanism with drospirenone POPs
- Impaired tubal motility - slows sperm transport
The short half-life of norethindrone requires a strict 3-hour timing window daily. - Textbook of Family Medicine, p. 638
Usage Method
How to Take
- 28 tablets per pack, taken one daily with no break between packs
- Must be taken at the same time every day - this is critical
- Norethindrone/norgestrel: timing window is 3 hours (if >3 hours late = missed pill)
- Drospirenone: timing window is 24 hours (if pill is <48 hours late = take ASAP; if ≥48 hours late = 7-day backup needed)
Starting
- Can be started at any time in the cycle ("quick start")
- If started >5 days after the beginning of a period, use backup contraception for the first 2 days (norethindrone/norgestrel) or 7 days (drospirenone)
- Can be started immediately postpartum, including while breastfeeding (unlike combined pills, progestins do not suppress milk production)
Missed Pill Rules
| Formulation | Missed Definition | Action |
|---|---|---|
| Norethindrone / Norgestrel | >3 hours late | Take ASAP, use backup for 2 days |
| Drospirenone | <48 hours late | Take ASAP, continue as normal |
| Drospirenone | ≥48 hours late | Take ASAP + use backup for 7 days |
Vomiting/Diarrhea
If vomiting or severe diarrhea occurs within 3 hours of taking the pill, treat as a missed pill and use backup contraception. - ACOG
Efficacy
- Typical use: ~7-9 pregnancies per 100 women per year
- Perfect use: <1 pregnancy per 100 women per year
- Less effective than combined OCs with typical use, but equivalent with perfect use
- Drospirenone POPs may have higher effectiveness (closer to combined OC efficacy)
Brand Names
Norethindrone 0.35 mg (28-day active)
| Brand | Region |
|---|---|
| Micronor | USA / worldwide |
| Nor-QD | USA |
| Camila | USA (generic) |
| Errin | USA |
| Heather | USA |
| Tulana | USA |
| Nora-BE | USA |
| Jolivette | USA |
| Lyza | USA |
| Cerazette / Cerelle | Europe / UK (desogestrel 75 mcg - also POP) |
Drospirenone 4 mg (24 active + 4 placebo)
| Brand | Notes |
|---|---|
| Slynd | USA (FDA approved 2019) |
| Slinda | Europe/international |
Norgestrel 0.075 mg
| Brand | Notes |
|---|---|
| Ovrette | USA (discontinued) |
| Norgeston | UK/Europe |
Desogestrel 75 mcg (European POP - wider ovulation-suppression window of 12 hours)
| Brand | Notes |
|---|---|
| Cerazette | UK/Europe, most widely used European POP |
| Cerelle | UK generic |
| Azalia | UK |
Who Can Use POPs
POPs are especially suitable for:
- Breastfeeding women (no effect on milk supply - unlike estrogen)
- Women with contraindications to estrogen: migraines with aura, history of DVT/PE, uncontrolled hypertension, cardiovascular disease, smokers >35 years
- Women who tolerate combined pills poorly (nausea, headache)
- Immediately postpartum or post-abortion
Side Effects
- Irregular menstrual bleeding (most common)
- Acne
- Depression / mood changes
- Spotting or amenorrhea
- Note: drospirenone POPs carry a theoretical hyperkalemia risk (anti-mineralocorticoid effect) - monitor potassium in patients on ACE inhibitors, ARBs, or potassium-sparing diuretics
Drug Interactions
The following can reduce POP effectiveness:
- Rifampicin (enzyme inducer - most significant)
- Certain antiepileptics (carbamazepine, phenytoin, phenobarbital, topiramate)
POPs do not increase the risk of venous thromboembolism or cardiovascular disease, unlike combined estrogen-containing pills.
Sources: Lippincott Illustrated Reviews Pharmacology, p. 849 | Textbook of Family Medicine 9e, p. 638 | Harriet Lane Handbook 23e | CDC US SPR for Contraceptive Use | ACOG
Add back therapy dosage n duration
Reading File
Finding Sources
Searching the Web
add-back therapy GnRH agonist dosage duration regimen endometriosis 2024
Finding Sources
Reading Web Page
add back therapy dosage duration regimen norethindrone estrogen progestogen
Reading File
Reading File
I now have thorough information from both textbooks and peer-reviewed sources. Here is the comprehensive add-back therapy section to append to the previous POP answer:
Add-Back Therapy
What Is It?
Add-back therapy refers to the addition of low-dose estrogen, progestogen, or both to women receiving GnRH agonist (GnRHa) treatment (e.g., for endometriosis, fibroids, PCOS). GnRH agonists suppress estrogen to menopausal levels, causing hypoestrogenic side effects - hot flashes, vaginal dryness, bone mineral density (BMD) loss, and reduced libido. Add-back replaces just enough hormone to counteract these effects without re-stimulating endometriosis or reducing the therapeutic benefit.
Why It Exists - The "Estrogen Threshold Hypothesis"
Endometriotic tissue is stimulated by estrogen at levels higher than needed for symptom relief. Keeping estradiol in the 30-45 pg/mL range suppresses endometriosis while protecting bone. Add-back achieves this "therapeutic window."
GnRH Agonists Used (Before Add-Back Is Added)
| Drug | Formulation | Dose |
|---|---|---|
| Leuprolide (Leuprorelin) | Monthly IM depot | 3.75 mg/month |
| Leuprolide | 3-monthly IM depot | 11.25 mg/3 months |
| Goserelin | SC implant | 3.6 mg/28 days |
| Nafarelin | Intranasal spray | 200 mcg twice daily |
| Buserelin | Intranasal / SC | Various |
| Triptorelin | IM depot | 3.75 mg/month |
Add-Back Therapy Regimens - Dosage
1. FDA-Approved Regimen (only one formally approved in USA)
| Drug | Dose | Given With |
|---|---|---|
| Norethindrone acetate (NETA) | 5 mg orally, daily | Leuprolide acetate depot |
This is the only FDA-approved add-back regimen, based on a multicenter placebo-controlled trial showing it maintains pain relief, prevents BMD loss, and controls vasomotor symptoms for up to 12 months.
2. Progestin-Only Add-Back Regimens
| Drug | Dose | Duration |
|---|---|---|
| Norethindrone acetate (NETA) | 5 mg/day orally | Up to 12 months |
| Norethisterone | 1.2 mg/day | Up to 6 months |
| Medroxyprogesterone acetate (MPA) | 2.5-5 mg/day | Up to 6 months |
Note: Progestin-only add-back (medrogestone 10 mg/day) does NOT prevent bone loss. NETA 5 mg/day is protective, likely due to its partial metabolism to ethinyl estradiol.
3. Estrogen + Progestogen (Combined) Add-Back Regimens
These offer better bone protection than progestin alone and are used for extended therapy (up to 2 years):
| Estrogen Component | Progestogen Component | Route |
|---|---|---|
| Conjugated equine estrogens (CEE) 0.625 mg | + NETA 5 mg/day | Oral, daily |
| Conjugated equine estrogens (CEE) 0.625 mg | + MPA 2.5 mg/day | Oral, daily |
| 17β-Estradiol 2 mg | + Norethisterone acetate 1 mg | Oral, daily |
| 17β-Estradiol (low dose) | + Progestogen | Oral/transdermal |
CEE 1.25 mg was less well tolerated (higher dropout) - the 0.625 mg dose is preferred.
4. Tibolone Add-Back
| Drug | Dose | Notes |
|---|---|---|
| Tibolone | 2.5 mg/day orally | Has estrogenic, progestogenic, and androgenic activity; effective for vasomotor symptoms AND bone protection |
Tibolone is widely used in Europe as a single-agent add-back.
Duration of Add-Back Therapy
| Scenario | Recommended Duration |
|---|---|
| GnRHa alone (no add-back) | Maximum 6 months (bone loss risk beyond this) |
| GnRHa + progestin-only add-back | Up to 6-12 months |
| GnRHa + estrogen-progestogen add-back | Up to 12-24 months (2 years appears effective and safe) |
| FDA-approved NETA 5 mg add-back | Up to 12 months with monthly leuprolide |
Standard GnRHa course: 3-6 months (3 months may relieve pain as well as 6, but 6 months gives longer symptom-free interval before recurrence).
Monitoring During Add-Back Therapy
- DEXA scan (bone densitometry) at baseline and during extended therapy to monitor BMD
- Estradiol levels - target 30-45 pg/mL (too low = bone loss; too high = endometriosis stimulation)
- Vasomotor symptoms - guide adequacy of add-back
- No routine lab monitoring required for short courses
Key Principles
- Add-back does not reduce efficacy of GnRH agonist for pain relief or endometriosis suppression - this is well established
- Combined estrogen + progestogen add-back is more protective for bone than progestogen alone for extended use
- GnRH agonists should generally not be used in adolescents who have not yet reached peak bone mass, unless add-back is co-prescribed
- Return to fertility occurs promptly after stopping GnRHa + add-back (unlike DMPA)
- Add-back therapy also allows treatment of uterine fibroids beyond the standard 3-6 month pre-operative course when needed
Sources: Berek & Novak's Gynecology (pp. 674-675) | Katzung's Basic and Clinical Pharmacology 16e (p. 1057) | PMC10201290 - Surrey ES, GnRH agonists in endometriosis | CDC / ACOG guidelines
Neta progesterone brand name
Searching the Web
norethindrone acetate NETA brand names list USA international
Finding Sources
Quick Clarification First
NETA (Norethindrone/Norethisterone Acetate) is NOT natural progesterone - it is a synthetic progestin (19-nortestosterone derivative). Natural progesterone has separate brand names (Prometrium, Utrogestan). Both are listed below.
NETA - Norethindrone Acetate / Norethisterone Acetate
As a Solo Progestin (standalone tablet)
| Brand Name | Region | Use |
|---|---|---|
| Aygestin | USA | HRT, endometriosis, abnormal uterine bleeding, amenorrhea |
| Norlutate | Canada / International | Same indications |
| Primolut-N | Europe / Asia / International | Norethisterone (free base, not acetate - similar) |
| Norethisterone | UK/Europe (generic) | Delay menstruation, endometriosis, HRT |
As Add-Back Therapy (combined with estrogen)
| Brand Name | Composition | Use |
|---|---|---|
| Activella | Estradiol 1 mg + NETA 0.5 mg | HRT (menopause) |
| CombiPatch | Estradiol + norethindrone acetate (transdermal patch) | HRT |
| Mimvey | Estradiol 1 mg + NETA 0.5 mg | HRT (generic of Activella) |
| Lopreeza | Estradiol 1 mg + NETA 0.5 mg | HRT |
| Amabelz | Estradiol + NETA (patch) | HRT |
As Combined Oral Contraceptive (with Ethinyl Estradiol)
| Brand Name | Composition |
|---|---|
| Loestrin / Lo Loestrin Fe | EE 20 mcg + NETA 1 mg |
| Junel Fe | EE 20 mcg + NETA 1 mg |
| Blisovi Fe | EE 20 mcg + NETA 1 mg |
| Aurovela Fe | EE 20 mcg + NETA 1 mg |
| Microgestin Fe | EE 20 mcg + NETA 1 mg |
| Loestrin 24 Fe | EE 20 mcg + NETA 1 mg |
| Estrostep Fe | EE (triphasic) + NETA 1 mg |
As Leuprolide + Add-Back (fixed combination)
| Brand Name | Composition | Use |
|---|---|---|
| Lupaneta Pack | Leuprolide acetate 3.75 mg + NETA 5 mg tablets | Endometriosis add-back (FDA approved) |
Natural Progesterone (Micronized) - Separate Drug
| Brand Name | Form | Use |
|---|---|---|
| Prometrium | Oral capsule 100 mg, 200 mg | HRT, luteal phase support |
| Utrogestan | Oral / vaginal capsule 100 mg, 200 mg | HRT, ART (IVF support) |
| Crinone | Vaginal gel 4%, 8% | Luteal phase support / IVF |
| Endogest | Vaginal gel / capsule | ART / HRT |
| Cyclogest | Vaginal / rectal pessary 200 mg, 400 mg | Luteal support |
Key Difference: NETA vs. Progesterone
| Feature | NETA (Norethindrone Acetate) | Natural Progesterone |
|---|---|---|
| Type | Synthetic 19-norprogestin | Bioidentical / micronized |
| Partial conversion to estrogen | Yes (→ ethinyl estradiol) | No |
| Oral bioavailability | High | Low (needs micronization) |
| Bone protection (add-back) | Yes | Less established |
| VTE risk | Slight | Lower (considered safer) |
| Breast cancer risk | Slightly higher | Possibly lower |
| Brands | Aygestin, Norlutate | Prometrium, Utrogestan |
Sources: Drugs.com ingredient database | Berek & Novak's Gynecology | Cleveland Clinic Drug Reference
This is a shared conversation. Sign in to Orris to start your own chat.